Biotech | April 08, 2026
Stipple Bio raises $100M Series A to advance next-gen cancer therapies
The new capital is expected to fund the company through 2029
The new capital is expected to fund the company through 2029
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
The trial also demonstrated significant improvements across multiple secondary endpoints
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
Sharp increase in diabetes, hypertension and fatty liver in 30–50 age group
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Subscribe To Our Newsletter & Stay Updated
